SYNergize: Understanding spore-forming gut bacteria biology to target pathogens
SYNergize aims to characterize gut spore-formers to develop synbiotics that inhibit pathogens and combat antimicrobial resistance through enhanced understanding of sporulation and transmission processes.
Projectdetails
Introduction
Our intestinal microbiota consists of a dense community of microorganisms, highly adapted to the human gastrointestinal tract. Shared species between individuals indicate the presence of evolved and efficient transmission routes that ensure colonization of beneficial bacterial species.
Research Focus
Research has traditionally focused on blocking enteric pathogen transmission routes as a means to prevent disease. However, a greater focus on understanding the transmission routes of commensal gut bacteria is required to promote health.
Importance of Spores
Spores are resilient structures that maintain bacterial integrity in a dormant state for extended periods. My previous work has shown that spore formation is a prevalent phenotype in the intestinal microbiota that promotes transmission of anaerobic gut bacteria by maintaining viability in adverse aerobic environmental conditions until ingested by a new host.
Knowledge Gaps
Despite its importance, sporulation processes in commensal gut bacteria remain poorly understood.
Project Objectives
SYNergize will:
- Characterize the metabolic capabilities of gut spore-formers.
- Analyze spore composition and the environmental cues involved in spore formation and germination.
- Identify combinations of bacteria and nutrients that inhibit enteric pathogens.
Addressing Antimicrobial Resistance
SYNergize also seeks to provide new approaches to target the problem of increasing antimicrobial resistance in European healthcare systems. These probiotic isolate and prebiotic nutrient combinations can be used to create ‘synbiotics’, rationally designed and ingested to decolonize gut pathogens.
Potential Applications
A deeper understanding of sporulation processes could also allow spores to be used to effectively deliver anaerobic probiotic bacteria to the gut. By exploring transmission and colonization processes of intestinal spore-forming bacteria, SYNergize seeks to understand fundamental adaptations of our intestinal microbiota, which could provide new tools to target antibiotic-resistant pathogens.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.499.503 |
Totale projectbegroting | € 1.499.503 |
Tijdlijn
Startdatum | 1-4-2024 |
Einddatum | 31-3-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORKpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Microbial Synthetic in vivo Cell Therapy SystemsThe MiStiC project aims to develop Clostridium leptum as a stable chassis for localized drug production and delivery, targeting colorectal cancer through engineered biosensors and natural product pathways. | ERC Starting... | € 1.499.938 | 2023 | Details |
Harnessing Specialized Metabolism from AnaerobesThe AnoxyGen project aims to explore and harness the unique biosynthetic capabilities of anaerobic bacteria to discover novel metabolites and enhance biotechnological applications for health and ecology. | ERC Advanced... | € 2.499.859 | 2025 | Details |
Proteome-wide Functional Interrogation and Modulation of Gut Microbiome SpeciesThis project aims to identify and manipulate gut microbiome protein functions using high-throughput proteomics to develop targeted therapies for restoring microbial health. | ERC Starting... | € 1.499.980 | 2023 | Details |
Unraveling the regulatory networks in Streptomyces that switch on antibiotic production on demandThis project aims to unlock the expression of cryptic biosynthetic gene clusters in Streptomyces to enhance drug discovery and agricultural applications through innovative systems biology and ecological insights. | ERC Advanced... | € 3.343.206 | 2022 | Details |
CoRe Defense: fortifying the resident gut microbiota’s colonization resistance to combat intestinal bacterial infections.This project aims to develop personalized bacterial consortia to prevent gastrointestinal infections by investigating microbiota's protective role against pathogens. | ERC Starting... | € 2.035.888 | 2025 | Details |
Microbial Synthetic in vivo Cell Therapy Systems
The MiStiC project aims to develop Clostridium leptum as a stable chassis for localized drug production and delivery, targeting colorectal cancer through engineered biosensors and natural product pathways.
Harnessing Specialized Metabolism from Anaerobes
The AnoxyGen project aims to explore and harness the unique biosynthetic capabilities of anaerobic bacteria to discover novel metabolites and enhance biotechnological applications for health and ecology.
Proteome-wide Functional Interrogation and Modulation of Gut Microbiome Species
This project aims to identify and manipulate gut microbiome protein functions using high-throughput proteomics to develop targeted therapies for restoring microbial health.
Unraveling the regulatory networks in Streptomyces that switch on antibiotic production on demand
This project aims to unlock the expression of cryptic biosynthetic gene clusters in Streptomyces to enhance drug discovery and agricultural applications through innovative systems biology and ecological insights.
CoRe Defense: fortifying the resident gut microbiota’s colonization resistance to combat intestinal bacterial infections.
This project aims to develop personalized bacterial consortia to prevent gastrointestinal infections by investigating microbiota's protective role against pathogens.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTHiNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment. | EIC Pathfinder | € 3.194.343 | 2025 | Details |
MicroBioDx: karakterisatie van microbioom-gastheer interactiesTenWise en Predica ontwikkelen de MicroBioD om de complexe samenstelling van micro-organismen te analyseren en gerichte behandelingen voor dysbiose te faciliteren. | Mkb-innovati... | € 143.080 | 2021 | Details |
INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTH
iNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment.
MicroBioDx: karakterisatie van microbioom-gastheer interacties
TenWise en Predica ontwikkelen de MicroBioD om de complexe samenstelling van micro-organismen te analyseren en gerichte behandelingen voor dysbiose te faciliteren.